Abstract:C1 inhibitor therapy improves outcome in several animal models of inflammatory disease. These include sepsis and Gram negative endotoxin shock, vascular leak syndromes, hyperacute transplant rejection, and ischemia-reperfusion injury. Furthermore, some data suggest a beneficial effect in human inflammatory disease. In many inflammatory conditions, complement system activation plays a role in pathogenesis. The contact system also very likely is involved in mediation of damage in inflammatory disease. Therefore, the beneficial effect of C1 inhibitor has been assumed to result from inhibition of one or both of these systems. Over the past several years, several other potential anti-inflammatory effects of C1 inhibitor have been described. These effects do not appear to require protease inhibition and depend on non-covalent interactions with other proteins, cell surfaces or lipids. In the first, C1 inhibitor binds to a variety of extracellular matrix components including type IV collagen, laminin, entactin and fibrinogen. The biologic role of these reactions is unclear, but they may serve to concentrate C1 inhibitor at extravascular inflammatory sites. The second is a non-covalent interaction with C3b that results in inhibition of formation of the alternative pathway C3 convertase, a function analogous to that of factor H. The third is an interaction with E and P selectins on endothelial cells that is mediated by the Lewis(x) tetrasaccharides that are expressed on C1 inhibitor. These interactions result in suppression of leukocyte rolling and transmigration. The fourth interaction is the binding of C1 inhibitor to Gram negative bacterial endotoxin that results in suppression of endotoxin shock by interference with the interaction of endotoxin with its receptor complex on macrophages. Lastly, C1 inhibitor binds directly to Gram negative bacteria, which leads to suppression of the development of sepsis, as demonstrated in the cecal ligation and puncture model. These observations suggest that C1 inhibitor is a multi-faceted anti-inflammatory protein that exerts its effects through a variety of mechanisms including both protease inhibition and several different non-covalent interactions that are unrelated to protease inhibition.

C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis

Increased thromboinflammatory load in hereditary angioedema

Modulation of Protein C Activation by Histones, Platelet Factor 4, and Heparinoids

Hereditary Angioedema and Venous Thromboembolism: Where There's Smoke, There's Fire

Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits

Suppression of complement regulatory protein C1 inhibitor in vascular endothelial activation by inhibiting vascular cell adhesion molecule-1 action.

Anti-Vascular Permeability Of The Cleaved Reactive Center Loop Within The Carboxyl-Terminal Domain Of C1 Inhibitor

Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema

Protein C anticoagulant and cytoprotective pathways

A novel mutation in exon 8 of C1 inhibitor (C1INH) gene leads to abolish its physiological stop codon in a large Chinese family with hereditary angioedema type I.

Ile73Asn Mutation in Protein C Introduces a New N-linked Glycosylation Site on the First EGF-domain of Protein C and Causes Thrombosis

Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor

Contact System Activation and Bradykinin Generation in Angioedema: Laboratory Assessment and Biomarker Utilization

Protein C Thr315Ala Variant Results in Gain of Function but Manifests As Type II Deficiency in Diagnostic Assays.

C1 Inhibitor Prevents Gram-negative Bacterial Lipopolysaccharide-Induced Vascular Permeability.

Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology

Physiologic activities of the contact activation system

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

C1 inhibitor: biologic activities that are independent of protease inhibition.

Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity.

Inter-α-trypsin inhibitor heavy chain 4 (ITIH4) as a compensatory protease inhibitor in hereditary angioedema